Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.
Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers. Gynecol Oncol. 2026 Sep; 212:134-144.
PMID: 42594534
Androgen receptor as a therapeutic target in endometrial cancer: a narrative review.
Androgen receptor as a therapeutic target in endometrial cancer: a narrative review. Int J Gynecol Cancer. 2026 06; 36(6):104698.
PMID: 42070324
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix. J Immunother Cancer. 2026 Feb 11; 14(2).
PMID: 41672597
CD73 restrains mutant ß-catenin oncogenic activity in endometrial carcinomas.
CD73 restrains mutant ß-catenin oncogenic activity in endometrial carcinomas. JCI Insight. 2026 01 23; 11(2).
PMID: 41574604
Successful treatment of gynecologic malignancy with trastuzumab deruxtecan in three patients with HER2 mutations.
Successful treatment of gynecologic malignancy with trastuzumab deruxtecan in three patients with HER2 mutations. Gynecol Oncol Rep. 2025 Dec; 62:101974.
PMID: 41158157
The Ultrasonography Characteristics of Borderline Ovarian Tumor Subtypes.
The Ultrasonography Characteristics of Borderline Ovarian Tumor Subtypes. J Ultrasound Med. 2025 Nov; 44(11):2133-2146.
PMID: 40586438
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression.
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression. Cancer Cell. 2025 Aug 11; 43(8):1495-1511.e7.
PMID: 40578359
Endometrial carcinosarcoma without myoinvasion.
Endometrial carcinosarcoma without myoinvasion. Int J Gynecol Cancer. 2025 10; 35(10):101971.
PMID: 40731228
The search for new therapeutic options for uterine carcinosarcoma.
The search for new therapeutic options for uterine carcinosarcoma. Gynecol Oncol. 2025 Jun; 197:A1-A2.
PMID: 40500079
Prognostic value of isolated tumor cells in sentinel lymph nodes in intermediate-risk endometrial cancer: results from an international, multi-institutional study.
Prognostic value of isolated tumor cells in sentinel lymph nodes in intermediate-risk endometrial cancer: results from an international, multi-institutional study. Int J Gynecol Cancer. 2025 07; 35(7):101906.
PMID: 40382975